- Report: NYC department stores revamping beauty as competition heats up
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- CDC publishes guidelines for collaborative practice agreements
- Walgreens Infusion Services can save $10.8 million in healthcare costs annually
- A shot in the arm for pharmacy
NEW YORK — The battle against biogenerics is on, noted a report published in The New York Times Tuesday. As many as eight states have introduced legislation that would restrict generic competition of biological pharamceuticals so far this year and one, the Virginia House of Delegates, already passed such a measure by a 91-to-6 vote.
At the federal level biological manufactures are squaring off against their potential generic competitors on whether or not the generic equivalent can share the same generic name as the brand product, the NYT report noted. If no, then pharmacists will be unable to substitute one for the other even if a state were to allow biogenerics.